Optimization of 8-oxoadenines with toll-like-receptor 7 and 8 activity

Article abstract of DOI:10.1016/j.bmcl.2020.126984

Toll-like receptors 7 and 8 (TLR7/8) agonists are potent immunostimulants that are attracting considerable interest as vaccine adjuvants. We recently reported the synthesis of a new series of 2-O-butyl-8-oxoadenines substituted at the 9-position with various linkers and N-heterocycles, and showed that TLR7/8 selectivity, potency and cytokine induction could be modulated by varying the alkyl linker length and the N-heterocyclic ring. In the present study, we further optimized the oxoadenine scaffold by investigating the effect of different substituents at the 2-position of the oxoadenine on TLR7/8 potency/selectivity, cytokine induction and DC maturation in human PBMCs. The results show that introducing a 1-(S)-methylbutoxy group at the 2-position of the oxoadenine significantly increased potency for TLR7/8 activity, cytokine induction and DC maturation.

Full text of DOI:10.1016/j.bmcl.2020.126984

Journal Pre-proofs
Optimization of 8-oxoadenines with toll-like-receptor 7 and 8 activity
Hélène G. Bazin, Laura S. Bess, Mark T. Livesay, Yufeng Li, Van Cybulski,
Shannon M. Miller, David A. Johnson, Jay T. Evans.
PII:
S0960-894X(20)30044-5
DOI:
https://doi.org/10.1016/j.bmcl.2020.126984
BMCL 126984
Reference:
Bioorganic & Medicinal Chemistry Letters
To appear in:
Received Date:
Revised Date:
Accepted Date:
29 October 2019
17 January 2020
19 January 2020
Please cite this article as: Bazin, H.G., Bess, L.S., Livesay, M.T., Li, Y., Cybulski, V., Miller, S.M., Johnson, D.A.,
T. Evans., J., Optimization of 8-oxoadenines with toll-like-receptor 7 and 8 activity, Bioorganic & Medicinal
Chemistry Letters (2020), doi: https://doi.org/10.1016/j.bmcl.2020.126984
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover
page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will
undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing
this version to give early visibility of the article. Please note that, during the production process, errors may be
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
© 2020 Published by Elsevier Ltd.

Optimization of 8-oxoadenines with toll-like-receptor 7 and 8 activity.
Hélène G. Bazin,a,b,d,* Laura S. Bess,a,b,d Mark T. Livesay,a,b,d Yufeng Li,d Van Cybulski,a,c,d
Shannon M. Miller,a,c David A. Johnson,d and Jay T. Evans.a,c,d
a Center for Translational Medicine, University of Montana, Missoula, Montana 59812, United States
b Department of Biomedical and Pharmaceutical Sciences, University of Montana, Missoula, Montana 59802, United
States.
c Division of Biological Sciences, University of Montana, Missoula, Montana 59802, United States
d GSK Vaccines, 553 Old Corvallis Road, Hamilton, MT 59840, United States
KEYWORDS. Toll-Like-Receptor, TLR7, TLR8, oxoadenine.
ABSTRACT: Toll-like receptors 7 and 8 (TLR7/8) agonists are potent immunostimulants that are
attracting considerable interest as vaccine adjuvants. We recently reported the synthesis of a new
series of 2-O-butyl-8-oxoadenines substituted at the 9-position with various linkers and N-
heterocycles, and showed that TLR7/8 selectivity, potency and cytokine induction could be
modulated by varying the alkyl linker length and the N-heterocyclic ring. In the present study, we
further optimized the oxoadenine scaffold by investigating the effect of different substituents at
the 2-position of the oxoadenine on TLR7/8 potency/selectivity, cytokine induction and DC
maturation in human PBMCs. The results show that introducing a 1-(S)-methylbutoxy group at the
2-position of the oxoadenine significantly increased potency for TLR7/8 activity, cytokine
induction and DC maturation.
Despite the success of vaccines in eradicating or reducing the incidence of some infectious
diseases such as smallpox, polio and measles, there is still an urgent need for the development of
effective vaccines against endemic pathogenic viruses (HIV, influenza), newly emerging diseases
(Zika, Chikungunya viruses) and global killers (tuberculosis and cancer). The development of new

adjuvants that are able to shape, enhance and prolong specific immune responses are critical to the
success of new vaccines. Adjuvants currently approved as part of licensed vaccines1 are safe and
effective at increasing humoral immunity, but have limited capacity to generate potent and durable
cell-mediated immune response, which is critical for the protection against many viral diseases
and cancers.2
Toll-like receptors (TLR) are expressed on immune cells and recognize many different
exogenous pathogen-associated molecular patterns (PAMPs). Because TLRs play a crucial role in
innate and adaptive immunity, their agonists are being extensively investigated as vaccine
adjuvants.3,4 Upon recognition of PAMPs, TLRs trigger the induction of cytokines and co-
stimulatory molecules, leading to the recruitment of cellular mediators critical for initiating innate
and adaptive immune responses. There are ten known human TLRs including five TLRs (1, 2, 4,
5, 6) that sense bacterial components and four TLRs (3, 7, 8, 9) that are located in cytoplasmic
compartments and recognize viral RNA (TLRs 3, 7, 8) and unmethylated DNA (TLR9).5 Human
TLR7 is mostly found on plasmacytoid DC and B cells and upon activation triggers the IRF7 and
NFκB pathways, leading to the induction of IFNα and proinflammatory cytokines, respectively.
Expression of human TLR8 mainly occurs on monocytes, macrophages, neutrophils and
conventional DCs and its activation leads to proinflammatory cytokines. 1H-imidazo[4,5-
c]quinolines6 (Imiquimod and Resiquimod, Figure 1) and 8-hydroxyadenines7 (SM360320 and
GSK2245035, Figure 1) are small molecule mimetics of ssRNA that activate TLR7/8. Imiquimod
is the only approved TLR7/8 agonist and is used for the topical treatment of certain skin
conditions.8 The use of imiquimod and resiquimod as vaccine adjuvants has led to mixed results.4
Some clinical trials have also been suspended over safety concerns9-13 following serious side-
effects observed upon administration of TLR7/8 agonists due to rapid systemic cytokine

distribution. Thus there is a need to develop safer and more effective TLR7/8 agonists as vaccine
adjuvants.
NH2
NH2
N
N
N
N
N
O
N
OH
Resiquimod (R848)
Imiquimod
NH2
N
NH2
N
NH2
H
N
H
N
H
N
N
N
N
O
O
O
R
O
N
N
N
X
O
O
N
1 4
-
n
SM360320
GSK2245035
N
5
N
R'
Figure 1. Structures of known imidazoquinolines and oxoadenines, and oxoadenines 1-4.
In the course of our own program aimed at developing safe and effective TLR7/8 agonists as
vaccine adjuvants, we synthesized and evaluated a series of twenty-seven new 2-O-butyl 8-
oxoadenines substituted at the N-9 position with different N-heterocycles linked to the oxoadenine
via alkyl linkers.14,15 We demonstrated that TLR7/8 selectivity/potency and cytokine induction
could be modulated by varying the length of the alkyl linker and correlated to the N-heterocycle
ring size while the ring chirality had little effect on biological activity. We also reported that the
N-heterocycle ring could be further substituted with amino- or hydroxyl-alkyl groups (Scheme 1,
3a and 4a) without negatively impacting biological activity.15 We are interested in developing such
N-heterocyclic oxoadenines for several reasons. In addition to their water-soluble salt forming
ability, the NH and OH groups in oxoadenines 1-4 (Figure 1) can be further derivatized.
Derivatization that can increase the cellular uptake of TLR7/8 agonists into endosomal/lysosomal
compartments of DCs where TLR7 and TLR8 reside16 are of considerable interest. To this end, we
are investigating lipid conjugation of imidazoquinolines17,18 and oxoadenines since lipid
conjugation of nucleoside drugs, including TLR7/8 agonists,19,20 is known to facilitate endocytosis

and decrease toxic side effects. Additionally, formulation of such nucleolipids into liposomes and
other nanoparticle systems is expected to help protect the drug from degradation, further reduce
toxicity and improve immunogenicity via a depot effect.21
In this letter, we report further optimization of the 8-oxoadenine scaffold by investigating the
effect of different substituents at the C-2 position of the 8-oxoadnine scaffold on TLR7/8 potency
and selectivity, and on cytokine (IFNα and TNFα) induction in human peripheral blood
mononuclear cells (hPBMCs). The ability of these oxoadenines to induce DC maturation was also
evaluated by measuring expression levels of major histocompatibility complex (MHC)
molecules22 (MHC-I and HLA-DR) and co-stimulatory ligands23 (CD80 and CD86) in hPBMC.
We first evaluated five 2-substituted analogs of the 2-O-butyl-9-methylpiperidinyl-8-
oxoadenine 1a.14 The substituents investigated are 1-(S)-methylbutoxy (1b), 1-(R)-methylbutoxy
(1c), methoxyethoxy (1d), 4-hydroxybutoxy (1e) and n-aminobutyl (1f). We choose to limit the
linear length of the 2-substituent to 4 and 5 atoms since optimal activity of similar oxoadenines
has been observed with chain length ranging from 4 to 6 atoms.7,24 Oxoadenines 1a-f were prepared
in two steps by alkylation of the corresponding intermediate 2-substituted-8-methoxyadenines 6a-f
with the requisite N-t-butoxycarbonyl (Boc)-protected 1-bromomethylpiperidine and acidic
deprotection (Scheme 1). Intermediates 6a-f were prepared from 2-chloro-6-amino-9-
tetrahydropyran adenine 525 in 4 steps following published procedures26-28 (Scheme 1).

NH2
N
H
N
NH2
N
N
NH2
N
H
N
.HCl
O
NH2
N
R
N
N
N
N
O
N
O
.HCl
vii-vi
N
v-vi
i-iv
R
N
N
X
OMe
Cl
R
N
H
X
O
n
N
HN
X = O, R = -Bu, n = 1
5
1a
1b
1c
1d
1e
1f
n
6a
6b
6c
6d
6e
6f
n
R'
X = O, R = -Bu
X = O, R = ( -2-Pent, n = 1
S)
X = O, R = ( -2-Pent
S)
3a
n
R = -Bu, R' = OH
X = O, R = ( -2-Pent, n = 1
R)
X = O, R = ( -2-Pent
R)
3b
4a
4b
S)
R = ( -2-Pent, R' = OH
X = O, R = MeO(CH2)2, n = 1
X = O, R = MeO(CH2)2
R = -Bu, R' = NH2
n
S)
X = O, R = -Bu(OH), n = 1
n
X = O, R = -Bu(OH)
n
R = ( -2-Pent, , R' = NH2
X = NH, R = -Bu, n = 1
n
X = NH, R = -Bu
n
2a
2b
n
X= O, R = -Bu, n = 5
S)
X = O, R = ( -2-Pent, n = 5
o
o
Scheme 1
6a,d
(6b-c)
C
. Reagents and conditions: (i) t-BuONa, R-OH, 100 C (
) or 70
, 1-4 days, 58-85%; or
6f
; or n-BuNH2, n-PrOH, 130 C, 8 h, 96% ( ); (ii) NBS,
o
o
(6e)
TBSO(CH2)4OH, t-BuONa, 55 C, 2.5 days, 63%
CHCl3, 0 oC to rt, 4 h; (iii) NaOMe, CH3OH, , 4 h, 75-78% (2 steps); (iv) TFA, CH3OH, rt, 3 days, 83-90%; (v)
K2CO3, 4-bromoalkyl-N-Boc-piperidine, DMF, 50 oC, 16 h; (vi) 4 N HCl/dioxane, CH3OH, rt, 1 h, 61-90% (2 steps);
(vii) K2CO3, Br(CH2)2OTBS or Br(CH2)2NHBoc, DMF, 50 oC, 16 h, 53-70%.
Oxoadenines 1a-f were first assessed for human (h) TLR7 and TLR8 activity, and for cytokine
induction (IFNα and TNFα) in human PBMCs, and compared to the known benchmarks
imidazoquinoline resiquinod (R848, a dual TLR7/8 agonist) and Sumitomo oxoadenine
SM360320 (TLR7 agonist). The hTLR7 and hTLR8 activity of the compounds was assessed by a
reporter gene assay using HEK293 cells stably transfected with either hTLR7 or hTLR8 and the
NFκB SEAP (secreted embryonic alkaline phosphatase) reporter. This assay measures NFκB
mediated SEAP production following TLR7- or TLR8-specific activation. Since the HEK reporter
assay only measures the NFκB pathway, additional assay systems would be necessary to evaluate
the IRF7 pathway activation by TLR7 agonists. Of note, the TLR7/8 potency values we previously
published14 for 1a and 2a were determined using an in-house derived stably transfected HEK293
cell line. The current study uses commercially obtained HEK293-hTLR7 and -hTLR8 NFkB-
SEAP reporter cells from Novus Biologicals (Littleton, CO) and Invivogen (San Diego, CA),
respectively, resulting in some changes in EC50 values and in TLR7/8 specificity from the
previously published findings.
Replacing the O atom at the 2-position (1a) with a N atom (1f) led to a two-fold reduction in
hTLR7 EC50 (Table 1 and Figure S1). Substituting the third C atom in the 2-O-butoxy group (1a)

with an oxygen (1d) or adding a terminal hydroxyl group to the 2-O-butoxy group (1e) led to a
significant decrease in hTLR7 activity, and the corresponding EC50 for 1e and 1f could not be
calculated within the μM dose range evaluated. Introducing a (S)-methyl group α to the 2-O atom
(1b) increased hTLR7 potency seven-fold while the corresponding R-isomer 1c was about two
times less potent than 1a. Oxoadenines 1a-f were less hTLR7/NFκB potent than the benchmark
TLR7/8 ligands R848 and SM360320. Similar results were observed for hTLR8 activity.
Table 1. Chemical Structures, TLR7 and TLR8 Activity and Cytokines induction of 8-
Oxoadenines
NH2
H
N
N
O
N
R
N
n
N
R'
IFNα
PC
TNFα
MEC
PLa
TLR7
EC50 (μM) EC50 (μM)
TLR8
Compound
R
n
R’
MEC
(μM)
PL
(μM) (pg/mL) (μM) (pg/mL)
R848
--
--
--
--
--
0.75±0.08 5.87±0.40 0.08
10
1408
2.0
19750
O
*
*
SM360320
1.17±0.30
--
0.08
0.08
0.08
1444
2.0
1663
O
O
1a
1b
1
1
H
H
19.8±2.6 326±626
0.4
5899
5473
2.0
0.4
2861
2.68±0.57 2.53±1.31 0.0032 0.016
12456
*
O
1c
1
H
35.8±4.6 619±115
0.08
0.4
6210
10
185
*
*
O
O
O
1d
1e
1f
1
1
1
5
H
H
H
H
>500
>500
>500
--
10
--
10
--
2240
--
--
--
--
--
HO
*
O
*
*
40.0±15.2 >500
0.08
0.4
5983
4678
--
--
NH
O
2a
0.45±0.10
0.24±0.08
--
--
0.00064 0.016
0.4
2874
2b
3a
3b
4a
4b
5
1
1
1
1
H
<0.00001 0.0032 2642
0.08
10
3015
2738
*
*
O
O
*
*
23.1±2.2 12.5±3.9
0.4
0.4
0.08
0.4
4731
4746
3045
4415
OH
4.06±0.56 2.14±0.51 0.016
2.0
2.0
2.0
10257
6133
*
*
OH
O
O
*
30.0±4.8 13.0±5.4
0.4
NH2
*
6.71±1.13 2.13±0.61 0.016
0.08
19307
*
NH2
O
EC50s are mean values and SD of three (TLR7) or four independent experiments (TLR8) conducted with HEK293-hTLR7
a
or HEK293-hTLR8 cells treated for 24 hours with the indicated compounds. PL (peak cytokine level) at 10 μM; MEC
(minimum effective concentration; lowest dose tested that induced cytokine), PC (peak concentration, dose inducing the
highest PL). PL, MEC and PC are representative data from one out of three independent donors.

The 1-(S)-methyl-butoxy oxoadenine 1b was again the most potent oxoadenine of the series with
over a 100-fold increase in hTLR8 potency compared to the n-butyloxy derivative 1a (Table 1 and
Figure S1). Oxoadenine 1c was about two-fold less potent than 1a while oxoadenines 1d-f had
negligible activity and their EC50s could not be calculated in the µM range evaluated. The much
larger increase of potency for TLR8 (>100-fold) over TLR7 (7-fold) observed when adding the
(S)-methyl substituent to 1a indicates that changes at the 2-position of the oxoadenine scaffold
have a much greater effect on the hTLR8 receptor than on the hTLR7 receptor. Oxoadenine 1b
was about two-fold more hTLR8 potent than R848. As expected, these compounds did not activate
hTLR3 or hTLR9, as shown by the lack of SEAP induction observed after stimulation of HEK293-
hTLR3 or HEK293-hTLR9 cell lines with compounds 1a-e (Figure S2), confirming the TLR7/8
selectivity of the compounds evaluated.
The 1-(S)-methylbutoxy oxoadenine 1b was the most potent IFNα inducer of the series with a
minimum effective concentration (MEC) 25-fold lower than observed for the butyloxy oxoadenine
1a (Table 1 and Figure S2). Butyloxy (1a), 1-(R)-methylbutoxy (1c) and butylamine- (1f) analogs
displayed similar IFNα induction profile (similar MEC, peak concentration (PC) and peak level
(PL)) while the methoxyethoxy oxoadenine 1d induced IFNα only at the highest dose tested. These
results are consistent with the literature data.7,24,27 The hydroxybutyloxy derivative (1e) was
inactive across the dose range evaluated. Oxoadenines 1a-c,f were more potent IFNα inducers than
R848 and SM360320. The IFNα production from hPBMCs, which occurs via activation of the
TLR7/IRF7 pathway, cannot be correlated to the hTLR7 activity observed in the HEK293-hTLR7
assay because the HEK assay only provides a read-out for the TLR7/NFκB pathway. In terms of
TNFα induction from primary human PBMCs, the 1-(S)-methylbutoxy oxoadenine 1b was also
the most potent oxoadenine of the series (Table 1 and Figure S2) followed by the butyloxy

oxoadenine 1a. The 1-(R)-methylpentoxy oxoadenine 1c induced a very small amount of TNFα at
the highest dose tested while the remaining oxoadenines were inactive. These results mirror the
hTLR8 (NF-κB) responses from the HEK293 cells. Comparing cytokine induction observed for
1a and 1f indicates that when changing the heteroatom at the 2-position from oxygen to nitrogen,
IFNα induction is maintained while TNFα induction is abrogated. Oxoadenines 1a-f were less
inflammatory than the benchmark imidazoquinoline compound R848.
In order to investigate if the enhancement of TLR7/8 potency and cytokine induction observed
upon introducing a (S) methyl group to the 2-butyloxy chain is maintained across different 9-N
substituted oxoadenines, we also synthesized the 1-(S)-methylbutoxy analogs (2b-4b) of
oxoadenines 2a,14 3a15,29 and 4a.15,29 Oxoadenine 2b30 was prepared by N-alkylation of
intermediate 6b with the requisite 1,1-dimethylethyl 4-(5-bromopentyl)-1-piperidine carboxylate14
followed by acidic deprotection (Scheme 1). Oxoadenines 3b and 4b were prepared in two steps
from 1b by alkylation of the piperidinyl N atom with (2-bromoethyl)-t-butyldimethylsilane or 2-
[(t-butoxycarbonyl) amino] ethyl bromide and acidic deprotection (Scheme 1). Introducing a (S)-
methyl group to the 2-butyloxy chain of oxoadenines 2a-4a increased hTLR7 potency as shown
by the 4- to 6-fold reduction in EC50s of oxoadenines 2b-4b (Table 1 and Figure S1). This potency
increase was similar to the one (7-fold) observed between 1a and 1b. hTLR8 potency of
oxoadenines 3b and 4b was also enhanced 6-fold. hTLR8 activity of 2a and 2b was very low
(Figure S1) and the corresponding hTLR8 EC50s could not be calculated in the μM dose range
evaluated. Oxoadenines 3a, 3b, 4a and 4b were slightly TLR8-selective. Both 1-(S)-methylbutoxy
oxoadenines 3b and 4b had an IFNα MEC 25-fold lower than the corresponding butyloxy
oxoadenines 3a and 4a, similar to the MEC decrease (25-fold) observed between 1a and 1b. While
IFNα peak levels for 1-(S)-methylpentoxy oxoadenines 1b, 3b and 4b were similar or higher than

the corresponding butyloxy oxoadenines 1a, 3a and 4a, the most potent 1-(S)-methylpentoxy
oxoadenines 2b induced lower IFNα peak levels than the corresponding butyloxy oxoadenine 2a.
Oxoadenines 2-4 were all more potent IFNα inducer than R848 and oxoadenines 2a and 2-4b were
more potent IFNα inducer than SM360320. Although oxoadenines 3b and 4b displayed higher
MEC than SM360320, these oxoadenines induced higher IFNα peak levels. As observed for 1a/1b,
introduction of a (S)-methyl group to oxoadenines 2a and 3a led to a 5-fold decrease in TNFα
MEC (Table 1 and Figure S2). While introducing the (S) methyl group to 4a did not decrease the
TNFα MEC concentration of 4b, this small substitution drastically increased TNFα PL induced by
4b, and 4b was equivalent to R848 for TNFα induction in the dose range tested. Oxoadenines 2a-b
had the lowest TNFα MEC but also induced the lowest TNFα peak levels.
Oxoadenines 1-4 were also evaluated for their ability to induce DC maturation at a single 0.1
µM dose in hPBMCs, by measuring the levels of major histocompatibility complex (MHC)
molecules22 (MHC-I and HLA-DR) and co-stimulatory ligands23 (CD80 and CD86) by flow
cytometry. As expected, the least TLR7/8 active oxoadenines 1d,e did not stimulate the production
of any of the four DC maturation markers investigated in either mDCs or pDCs (Figures 2 and 3).
In mDCs, increase of MHC-I stimulation was only observed for oxoadenines 2a,b, albeit at a
modest level (1.3 to 1.4-fold, Figure 2A). Oxoadenines 1b, 2a,b and 3b also led to a 1.6- 2.7- and
1.5-fold increase of CD80 stimulation in mDCs, respectively (Figure 2B), although the large
variance observed between the three donors tested would require testing in additional donors to
draw a firm conclusion. Oxoadenines 1-4 induced no HLA-DR or CD86 in mDCs (Figures 3A-
B). While R848 was also ineffective at inducing HLA-DR (Figure 3A) and CD80 in mDCs (Figure
2B), it induced a 1.4- and 1.9-fold increase in MHC-I (Figure 2A) and CD86 (Figure 3B) levels in
mDCs, respectively.

3
2
1
0
5
4
3
2
1
0
A
C
B
D
f
f
a
c
e
8
a
a
a
a
c
e
8
a
a
a
4
b
d
b
b
b
b
d
b
b
b
4
1
1
1
1
1
4
2
3
4
1
1
1
4
8
2
3
1
1
2
3
4
1
1
2
3
8
R
R
4
10
8
3
2
1
0
6
4
2
0
f
f
a
c
e
8
a
a
a
4
b
d
b
b
b
4
a
c
e
8
a
a
a
4
b
d
b
b
b
4
1
1
1
1
1
4
2
3
1
1
2
3
1
1
1
4
2
3
1
1
2
3
8
8
R
R
Figure 2. Fold-change of (A) MHC-I and (B) CD80 levels in mDCs; (C) MHC-I and (D) CD86
levels in pDCs, after 6 h stimulation with oxoadenines 1-4 compared to unstimulated cells. Data
is mean values of three independent experiments in three different donors (2 donors for R848
except for CD80 with 1 donor). Error bars indicate SD.
1.5
1.0
0.5
0.0
2.5
2.0
1.5
1.0
0.5
0.0
A
B
f
f
a
c
e
8
4
a
a
a
a
c
e
8
4
a
a
a
4
b
d
b
b
b
b
d
b
b
b
4
1
1
1
1
1
2
3
4
1
1
1
2
3
1
1
2
3
4
1
1
2
3
8
8
R
R
3.5
2.8
2.1
1.4
0.7
0.0
3.5
2.8
2.1
1.4
0.7
0.0
C
D
f
f
a
c
e
8
4
a
a
a
a
c
e
a
a
a
4
b
d
b
b
b
b
d
8
4
b
b
b
4
1
1
1
1
1
2
3
4
1
1
1
2
3
1
1
2
3
4
1
1
2
3
8
8
R
R
Figure 3. Fold-change of (A) HLA-DR and (B) CD86 levels in mDCs; (C) HLA-DR and (D) CD80
levels in pDCs, after 6 h stimulation with oxoadenines 1-4 compared to unstimulated cells. Data
is mean values of three independent experiments in three different donors (2 donors for R848
except for CD80 with 1 donor). Error bars indicate SD.

The low DC maturation activity induced by only a few of the oxoadenines tested on mDCs is not
unexpected since mDCs express TLR8 and most of the oxoadenines tested are weak TLR8
agonists. In general, oxoadenines 1-4 were more active in pDCs, which was expected since these
oxoadenines are TLR7 agonists and human pDCs express TLR7. In pDCs, oxoadenines 1a-c and
2-4 induced a 1.2- to 2.4-fold increase in MHC-I (Figure 2C) and HLA-DR levels (Figure 3C).
Introducing a 1-(S)-methyl group to the 2-butyloxy chain of oxoadenines 3a and 4a increased
MHC-I and HLA-DR stimulation by 1.5-1.7-fold. Compounds 2a,b induced a similar 1.7-2.3-fold
increase in MHC-I and HLA-DR stimulation but introduction of the 2-α methyl group in 2b did
not increase stimulation levels as observed with 3-4. Oxoadenines 1c-e, 3a and 4a were mostly
inactive for CD86 (Figure 2D) and CD80 (Figure 3D) activation, while 1a and 1b induced a 1.4-
and 2.0-fold increase of CD86 levels, respectively. As previously observed for MHC-I and HLA-
DR upregulation, adding the 2-α methyl group to 3a and 4a led to a 1.7- to 2.3-fold increase in
CD86 levels, but did not further increase the activity of 2b. The most potent oxoadenines tested
were as potent as R848 with respect to MHCI and II upregulation in pDCs but less potent than
R848 with respect to CD86 upregulation.
In conclusion, the data described herein show that the TLR7/8 activity of oxoadenines can be
modulated by the substituent at the C-2-position. Replacing the oxygen atom at the 2-position with
a nitrogen atom led to a less potent oxoadenine and abrogation of TNFα induction while
introducing an oxygen or hydroxyl in the C-2 butyl side-chain drastically decreased TLR7/8
activity. Introducing an α-(S) methyl group on the 2-butyloxy side chain increased TLR7/8
potency, cytokine induction and upregulation of some DC maturation markers. The α-(S)
methylated oxoadenines 3b and 4b were the most TLR8 active oxoadenines of the series with EC50

< 5 µM. Oxoadenine 3b has been selected for further phospholipidation and the resulting
phospholipidated oxoadenine is being evaluated as a vaccine adjuvant.
Acknowledgements
The authors thank Lois Walsh and Rebekah Tee for formulation of the compounds described in
this study, Clara Davison for performing the hTLR3 and hTLR9 assay, and GlaxoSmithKline
where the compounds were first prepared and tested under NIAID contract HHSN272200900036C
prior to Novation of the contract to the University of Montana for completion of the work
described.
AppendixA. Supplementary data
Supplementary data to this article can be found online.
Corresponding Author
* Phone: 406-360-6682. E-mail: helene.bazin-lee@mso.umt.edu.
Present Addresses
1 Transcenta, 51 Sawyer Road, Suite 220, Waltham, MA 02453, Boston, United States.
Conflict of Interest Disclosure
HGB, LSB, MTL, YL, VC, DAJ and JTE were employees of the GSK group of companies at
the time of the synthesis and initial in vitro characterization of the compounds (HEK293 and
PBMC assays). HGB, LSB, MTL, VC and JTE became employees of the University of Montana
where additional compound synthesis/characterization and in vitro testing (HEK293, PBMC and
DC maturation markers) were completed. HGB, YL and DAJ are inventors on patents covering
some of the oxoadenines described in this manuscript.
Funding Sources

This work was supported in part by the National Institute of Allergy and Infectious Diseases
(NIAID) under contract HHSN272200900036C (to Corixa Corporation d/b/a GlaxoSmithKline
Biologicals SA, novated to University of Montana) and by the Center for Translational Medicine
at University of Montana. Any opinions, findings, conclusions or recommendations expressed in
this article are those of the authors and do not necessarily reflect the views of the NIAID.
References
1. Lee, S.; Nguyen, M. T. Recent Advances of Vaccine Adjuvants for Infectious Diseases.
Immune Netw. 2015, 15, 51-57.
2 Woolard, S. N.; Kumaraguru, U. Viral Vaccines and CTL Response. J. Biomed. Biotechnol.
2010, Article ID 141657.
3. Dowling, J. K.; Mansell, A., Toll-like receptors: the swiss army knife of immunity and vaccine
development. Clin. Trans. Immunol. 2016, 5, e85.
4. Vasilakos, J. P.; Tomai, M. A. The use of Toll-like receptor 7/8 agonists as vaccine adjuvants.
Expert Rev. Vaccines. 2013, 12, 809-819.
5. De Nardo, D. Toll-like receptors: Activation, signaling and transcriptional modulation.
Cytokine. 2015, 74, 181-189.
6. Gerster, J. F.; Lindstrom, K. J.; Miller, R. L.; Tomai, M. A.; Birmachu, W.; Bomersine, S. N.;
Gibson, S. J.; Imbertson, L. M.; Jacobson, J. R.; Knafla, R. T.; Maye, P. V.; Nikolaides, N.;
Oneyemi, F. Y.; Parkhurst, G. J.; Pecore, S. E.; Reiter, M. J.; Scribner, L. S.; Testerman, T. L.;
Thompson, N. J.; Wagner, T. L.; Weeks, C. E.; Andre, J.-D.; Lagain, D.; Bastard, Y.; Lupu,
M. Synthesis and structure-activity-relationships of 1H-Imidazo[4,5-c]quinolines that induce
interferon production. J. Med. Chem. 2005, 48, 3481-3491.

7. Hirota, K.; Kazaoka, K.; Niimoto, I.; Kumihara, H.; Sajiki, H.; Isobe, Y.; Takaku, H.; Tobe,
M.; Ogita, H.; Ogino, T.; Ichii, S.; Ku-rimoto, A.; Kawakami, H. Discovery of 8-
hydroxyadenines as a novel type of interferon inducer. J. Med. Chem. 2002, 45, 5419-5422.
8. Hanna, E.; Abadi, R.; Abbas, O. Imiquimod in dermatology: an overview. Int. J. Dermatol.
2016, 55, 831-844.
9. Gunzer, M.; Riemann, H.; Basoglu, Y.; Hillmer, A.; Weis-haupt, C.; Balkow, S.; Benninghoff,
B.; Ernst, B.; Steinert, M.; Scholzen, T.; Sunderkötter, C.; Grabbe, S. Systemic administration
of a TLR7 ligand leads to transient immune incompetence due to peripheral-blood leukocyte
depletion. Blood. 2005, 106, 2424-2432.
10. Goldstein, D.; Hertzog, P.; Tomkinson, E.; Couldwell, D.; McCarville, S.; Parrish, S.;
Cunningham, P.; Newell, M.; Owens, M.; Cooper, D. A. Administration of imiquimod, an
interferon inducer, in asymptomatic human immunodeficiency virus-Infected persons to
determine safety and biologic response modification. J. Infect. Dis. 1998, 178, 858-861.
11. Savage, P.; Horton, V.; Moore, J.; Owens, M.; Witt, P.; Gore, M. E. A phase I clinical trial of
imiquimod, an oral interferon induc-er, administered daily. Br. J. Cancer. 1996, 74, 1482-
1486.
12. Horscroft, N. J.; Pryde, D. C.; Bright, H. Antiviral applica-tions of Toll-like receptor agonists.
J. Antimicrob. Chemother. 2012, 67, 789-801.
13. Perkins, H.; Khodai, T.; Mechiche, H.; Colman, P.; Burden, F.; Laxton, C.; Horscroft, N.;
Corey, T.; Rodrigues, D.; Rawal, J.; Heyen, J.; Fidock, M.; Westby, M.; Bright, H. Therapy
with TLR7 agonists Induce lymphopenia: correlating pharmacology to mecha-nism in a mouse
model. J. Clin. Immunol. 2012, 32, 1082-1092.

14. Bazin, H. G.; Li, Y.; Khalaf, J. K.; Mwakwari, S.; Livesay, M. T.; Evans, J. T.; Johnson, D. A.
Structural requirements for TLR7-selective signaling by 9-(4-piperidinylalkyl)-8-oxoadenine
derivatives. Bioorg. Med. Chem. Lett. 2015, 25, 1318-1323.
15. Evans JT, Bess LS, Mwakwari SC, et al. Synthetic Toll-Like Receptors 7 and 8 Agonists:
Structure-Activity Relationship in the Oxoadenine Series. ACS Omega 2019, 4, 15665-15677.
16. Lee, J.; Chuang, T.-H.; Redecke, V.; She, L.; Pitha, P. M.; Carson, D. A.; Raz, E.; Cottam, H.
B. Molecular basis for the im-munostimulatory activity of guanine nucleoside analogs:
Activation of Toll-like receptor 7. Proc. Natl. Acad. Sci. 2003, 100, 6646-6651.
17. Bazin, H. G.; Bess, L. S.; Livesay, M. T.; Mwakwari, S. C.; Johnson, D. A. Phospholipidation
of TLR7/8-active imidazoquino-lines using a tandem phosphoramidite method. Tetrahedron
Lett. 2016, 57, 2063-2066.
18. Mwakwari, S. C.; Bess, L. S.; Bazin, H. G.; Johnson, D. A., Efficient tin-mediated synthesis
of lysophospholipid conjugates of a TLR7/8-active imidazoquinoline. Tetrahedron Lett. 2016,
57, 2093-2096.
19. Chan, M.; Hayashi, T.; Kuy, C. S.; Gray, C. S.; Wu, C. C. N.; Corr, M.; Wrasidlo, W.; Cottam,
H. B.; Carson, D. A. Synthesis and immunological characterization of toll-like receptor 7
agonistic con-jugates. Bioconj. Chem. 2009, 20, 1194-1200.
20. Smirnov, D.; Schmidt, J. J.; Capecchi, J. T.; Wightman, P. D. Vaccine adjuvant activity of 3M-
052: An imidazoquinoline designed for local activity without systemic cytokine induction.
Vaccine 2011, 29, 5434-5442.
21. Rosemeyer, H. Nucleolipids: natural occurrence, synthesis, molecular recognition, and
supramolecular assemblies as potential precursors of life and bioorganic materials. Chem.
Biodivers. 2005, 2 977-1063.

22. Rock, K. L.; Reits, E.; Neefjes, J. Present yourself! By MHC class I and MHC class II
molecules. Trends Immunol. 2016, 37, 724-737.
23. Chen, L.; Flies, D. B. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat.
Rev. Immunol. 2013, 13, 227-242.
24. Kurimoto, A.; Ogino, T.; Ichii, S.; Isobe, Y.; Tobe, M.; Ogita, H.; Takaku, H.; Sajiki, H.;
Hirota, K.; Kawakami, H. Synthesis and evaluation of 2-substituted 8-hydroxyadenines as
potent interferon inducers with improved oral bioavailabilities. Bioorg. Med. Chem. 2004, 12,
1091-1099.
25. Borrmann, T.; Abdelrahman, A.; Volpini, R.; Lambertucci, C.; Alksnis, E.; Gorzalka, S.;
Knospe, M.; Schiedel, A. C.; Cristalli, G.; Müller, C.E. Structure-Activity Relationships of
Adenine and Deazaadenine Derivatives as Ligands for Adenine Receptors, a New Purinergic
Receptor Family. J. Med. Chem., 2009, 52, 5974-5989.
26. Lazarides, L., Smith, S.A.; Stocker, R.; Theobald, C.J. Purine derivatives as
immunomodulators. WO2008/101867, Feb 28, 2008.
27. Biggadike, K.; Ahmed, M.; Ball, D. I.; Coe, D. M.; Dalmas Wilk, D. A. Edwards, C. D.;
Gibbon, B. H.; Hardy, C. J.; Hermitage, S. A.; Hessey, J. O.; Hillegas, A. E.; Hughes, S. C.;
Lazarides, L.; Lewell, X. Q.; Lucas, A.; Mallett, D. N.; Price, M. A.; Priest, F. M.; Quint, D.
J.; Shah, P.; Sitaram, A.; Smith, S. A.; Stocker, R.; Trivedi, N. A.; Tsitoura, D. C.; Weller, V.
Discovery of 6-Amino-2-{[(1S)-1-methylbutyl]oxy}-9-[5-(1-piperidinyl)pentyl]-7,9-dihydro-
8H-purin-8-one e (GSK2245035), a highly potent and selective intranasal toll-like receptor 7
agonist for the treatment of asthma. J. Med. Chem. 2016, 59, 1711-1726.
28. Bazin-Lee, H; Coe, D. M.; Lazarides, L., Mitchell, C. J.; Smith, S.A.; Trivedi, N. Novel
adenine derivatives. WO2010/018134, Feb 18, 2010.

29. Johnson, D. Lipidated oxoadenine derivatives. US 9,044,481, Jun 02, 2015.
30. Bazin-Lee, H; Li, Y. Adenine derivatives which are useful in the treatment of allergic diseases
or other inflammatory conditions. WO2016/075661, May 19, 2016.
Graphical Abstract
EC50 (M)
X
R
n
R'
hTLR7 hTLR8
1a O n
1
1
1
1
1
1
5
5
1
1
1
1
H
H
H
H
H
H
H
H
19.8
2.68
35.8
>500
>500
40.0
0.45
0.24
326
2.53
>500
>500
--
>500
--
-Bu
1b
1c
1d
1e
O
O
O
O
S
( )-2-Pent
NH2
N
( )-2-Pent
CH3O(CH2)2
HO(CH2)4
R
N
N
N
O
R
1f N n
2a O n
-Bu
-Bu
X
2b
3a O n
O
S
--
( )-2-Pent
-Bu
n
(CH2)2OH 23.1
(CH2)2OH 4.06
(CH2)2NH2 30.0
(CH2)2NH2 6.71
12.5
2.14
13.0
2.13
3b
4a O n
O
S
( )-2-Pent
-Bu
N
R'
4b
O
S
( )-2-Pent